FDA warned ECI Pharmaceuticals for listing the wrong active ingredient for its estrogen and testosterone drugs, which got them removed from the NDC Directory.
What happened
FDA reviewed the drug listing information ECI Pharmaceuticals submitted through its electronic Drug Registration and Listing System (eDRLS) for two esterified estrogens and methyltestosterone products. FDA found the listing file named conjugated estrogens as an active ingredient, while the labeling sent with the listing named esterified estrogens, and said these are different and not equivalent ingredients. FDA had already sent the firm a deficiency letter on October 26, 2021 and a removal notification on December 10, 2021, after which the products were taken out of FDA's Online NDC Directory.
What FDA found
The listing file named conjugated estrogens as an active ingredient, but the labeling sent with it named esterified estrogens, so the listing did not give the correct name of each active ingredient.
FD&C Act section 510(j)(1)(C), 21 U.S.C. 360(j)(1)(C); 21 CFR 207Failing to list the drugs properly is a prohibited act under the FD&C Act.
FD&C Act section 301(p), 21 U.S.C. 331(p)Because the drugs were not properly listed with FDA, they are misbranded.
FD&C Act section 502(o), 21 U.S.C. 352(o); section 301(a), 21 U.S.C. 331(a)
What FDA wants
FDA asks the firm to write within 15 working days describing the specific steps taken to fix the violations, how it will prevent them from happening again, and copies of related documents. If the fixes cannot be finished in that time, the firm must explain the delay and say when they will be done.
Who should pay attention
- drug companies that submit their own NDC listing files to FDA
- regulatory affairs staff who keep eDRLS listing data in step with approved labeling
- pharmacies and prescribers who rely on NDC Directory entries
This is a summary. Read the original letter on fda.gov.